Abstract
Background The increasing burden of heart failure (HF) is a major unmet need for new therapeutics. No new drug has been approved for HF for over a decade. The natriuretic peptides as endogenous activators of particulate guanylyl cyclase (GC) receptors represent an unparalleled opportunity for novel therapeutic agents for HF. Specifically, the GC-A receptor activated by ANP and BNP and GCB activation by CNP mediate beneficial pleiotropic actions, which include natriuresis, vasodilatation, suppression of the renin-angiotensin-aldosterone system, inhibition of cardiomyocyte hypertrophy, retardation of fibrosis and improvement in ventricular function and structure.
Highlights
The increasing burden of heart failure (HF) is a major unmet need for new therapeutics
No new drug has been approved for HF for over a decade
The natriuretic peptides as endogenous activators of particulate guanylyl cyclase (GC) receptors represent an unparalleled opportunity for novel therapeutic agents for HF
Summary
The increasing burden of heart failure (HF) is a major unmet need for new therapeutics. Designer natriuretic peptides for heart failure: advanced in clinical development John Burnett Jr. From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
